Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.
Aileen I. Fernandez, PhD
Advertisement
Articles by Aileen I. Fernandez, PhD
Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.
Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.
Advertisement
Latest Updated Articles
Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast CancerPublished: December 14th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
2
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
3
Immune-Targeting Vaccine Shows Promise Intercepting Cancer in Patients With Lynch Syndrome
4
FDA Grants Orphan Drug Designation to Gotistobart in Squamous NSCLC
5